Cardiex Ltd
ASX:CDX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Cardiex Ltd
Research & Development
Cardiex Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardiex Ltd
ASX:CDX
|
Research & Development
-AU$2.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-3%
|
|
|
Somnomed Ltd
ASX:SOM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Research & Development
-AU$443.9k
|
CAGR 3-Years
6%
|
CAGR 5-Years
37%
|
CAGR 10-Years
-36%
|
|
|
Cochlear Ltd
ASX:COH
|
Research & Development
-AU$291.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Research & Development
-AU$4m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Cardiex Ltd
Glance View
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.
See Also
What is Cardiex Ltd's Research & Development?
Research & Development
-2.2m
AUD
Based on the financial report for Jun 30, 2025, Cardiex Ltd's Research & Development amounts to -2.2m AUD.
What is Cardiex Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-3%
Over the last year, the Research & Development growth was 11%. The average annual Research & Development growth rates for Cardiex Ltd have been 2% over the past three years , -29% over the past five years , and -3% over the past ten years .
